OnPoint Analytics
Retaining the right expert is often one of the most important decisions made in litigating a case. You need an expert witness with impeccable credentials, deep experience in the domain space, and superb communication skills. Behind that expert, you need a team to match. Together, they must function quickly and efficiently, responding to the almost limitless complexities of litigation. They need to see all the angles before delivering the right solution.
Learn more About Us , explore our Service Areas , and meet our diverse panel of Experts from across the country.
News
Our clients need to move rapidly and so do we. Each day is complete with its own series of challenges and accomplishments—a few of these are gathered in our News section.
In August 2024, OnPoint expert Dr. Gareth Macartney testified in the U.S. District Court in Waco, Texas, at a jury trial concerning the alleged infringement of...Read More
OnPoint patent damages expert witness, Dr. Gareth Macartney, testified as Amazon’s damages expert in TrackTime v. Amazon at a jury trial held in September, 2023 in...Read More
Since 2014, OnPoint has had the pleasure and honor of working with Dr. John Connor. This year, Dr. Connor announced that he will be retiring from...Read More
On May 14, 2021, U.S. District Judge Nathaniel M. Gorton, sitting in Massachusetts, certified a class of End-Payor Plaintiffs (EPPs) consisting of Third-Party Payors (TPPs) in...Read More
OnPoint congratulates agricultural economics expert witness, Dr. Jeffrey Dorfman, on his appointment as State Fiscal Economist by Georgia Governor Brian Kemp. In this role, Dr. Dorfman...Read More
OnPoint antitrust expert witness, Dr. Gareth Macartney, recently gave two days of deposition testimony in an antitrust and false claims lawsuit against Defendant Keurig Green Mountain....Read More
Biosimilars Tracker
More than a decade after its enactment, the Biologics Price Competition and Innovation Act is finally transforming the economic and therapeutic landscape for some of the world’s most important drugs. Having struggled with legal and practical implementation, the FDA is approving biosimilars designed as lower cost substitutes for major biologics. OnPoint’s Tracker collects current information on approved biosimilars, their cost and formulary status.
Visit OnPoint’s Biosimilars Tracker to see the latest information you need to know about currently approved biosimilars and their availability in the United States.
9 Reference Products29 Approved Biosimilars